Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma
Authors
Keywords
-
Journal
JAMA Oncology
Volume -, Issue -, Pages -
Publisher
American Medical Association (AMA)
Online
2023-10-05
DOI
10.1001/jamaoncol.2023.4003
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
- (2022) Lin Shen et al. JOURNAL OF CLINICAL ONCOLOGY
- Systemic Treatment of Advanced Unresectable Hepatocellular Carcinoma After First-Line Therapy: Expert Recommendations from Hong Kong, Singapore and Taiwan
- (2022) Thomas Yau et al. Liver Cancer
- Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances
- (2022) Kathrine S Rallis et al. World Journal of Clinical Oncology
- LBA35 Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial
- (2022) S. Qin et al. ANNALS OF ONCOLOGY
- Global burden of primary liver cancer in 2020 and predictions to 2040
- (2022) Harriet Rumgay et al. JOURNAL OF HEPATOLOGY
- Hepatocellular carcinoma
- (2021) Josep M. Llovet et al. Nature Reviews Disease Primers
- Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines
- (2021) A. Vogel et al. ANNALS OF ONCOLOGY
- Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer
- (2021) Jie Wang et al. JAMA Oncology
- O-1 Results from a global phase 2 study of tislelizumab, an investigational PD-1 antibody, in patients with unresectable hepatocellular carcinoma
- (2021) M. Ducreux et al. ANNALS OF ONCOLOGY
- Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
- (2021) Zhenggang Ren et al. LANCET ONCOLOGY
- 121O RATIONALE 309: A randomized, global, double-blind, phase III trial of tislelizumab (TIS) vs placebo, plus gemcitabine + cisplatin (GP), as first-line treatment for recurrent/metastatic nasopharyngeal cancer (RM-NPC)
- (2021) Y. Yang et al. ANNALS OF ONCOLOGY
- Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
- (2021) Thomas Yau et al. LANCET ONCOLOGY
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
- (2020) L.-T. Chen et al. ANNALS OF ONCOLOGY
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives
- (2020) Piera Federico et al. Cancers
- Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline
- (2020) John D. Gordan et al. JOURNAL OF CLINICAL ONCOLOGY
- RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma
- (2019) Shukui Qin et al. Future Oncology
- The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions
- (2018) Tong Zhang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- 76PTislelizumab, an anti-PD-1 antibody, in patients with urothelial carcinoma (UC): Results from an ongoing phase I/II study
- (2018) S Sandhu et al. ANNALS OF ONCOLOGY
- Prognosis of Unresectable Hepatocellular Carcinoma: Comparison of Seven Staging Systems (TNM, Okuda, BCLC, CLIP, CUPI, JIS, CIS) in a Chinese Cohort
- (2014) Jin-feng Zhang et al. PLoS One
- World Medical Association Declaration of Helsinki
- (2013) JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Design and rationale for the non-interventional Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib (GIDEON) study
- (2010) R. Lencioni et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started